Drug Treatment of Epilepsy
A special issue of Neurology International (ISSN 2035-8377). This special issue belongs to the section "Movement Disorders and Neurodegenerative Diseases".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 28
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue will provide a comprehensive overview of recent advances in understanding and treating seizures, with a particular emphasis on status epilepticus (SE). SE remains a neurological emergency that requires timely and effective intervention. Traditional stepwise treatment protocols often overlook early pharmacoresistance. In this context, we highlight the emerging concept of 'Stage 1 Plus'—a clinical framework identifying probable benzodiazepine-refractory SE even before first-line therapy is administered. By recognizing key features such as prolonged seizure durations, non-convulsive presentations, and acute symptomatic etiologies, Stage 1 Plus challenges conventional timing and drug sequencing strategies. For this Special Issue, we invite contributions addressing mechanistic insights, novel diagnostic approaches, and optimized therapeutic protocols for SE. In parallel, we encourage submissions exploring the landscape of new anti-seizure medications (ASMs) in epilepsy more broadly, including targeted therapies, precision medicine approaches, and drugs with unique mechanisms of action. Our aim is to foster a multidisciplinary dialogue that bridges clinical innovation, pharmacology, and translational neuroscience, ultimately aiming to improve seizure control and patient outcomes.
Dr. Giuseppe Magro
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Neurology International is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- status epilepticus
- status epilepticus treatment
- anti-seizure medications (ASMs)
- epilepsy
- epilepsy treatment
- seizure
- seizure treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
